Review

Getting to the Heart of Alzheimer Disease

Joshua M. Tublin,* Jeremy M. Adelstein,* Federica del Monte, Colin K. Combs, Loren E. Wold

Abstract: In a somewhat narrow diagnostic lens, Alzheimer disease (AD) has been considered a brain-specific disease characterized by the presence of Aβ (β-amyloid) plaques and tau neural fibrillary tangles and neural inflammation; these pathologies lead to neuronal death and consequently clinical symptoms, such as memory loss, confusion, and impaired cognitive function. However, for decades, researchers have noticed a link between various cardiovascular abnormalities and AD—such as heart failure, coronary artery disease, atrial fibrillation, and vasculopathy. A considerable volume of work has pointed at this head to heart connection, focusing mainly on associations between cerebral hypoperfusion and neuronal degradation. However, new evidence of a possible systemic or metastatic profile to AD calls for further analysis of this connection. Aβ aggregations—biochemically and structurally akin to those found in the typical AD pathology—are now known to be present in the hearts of individuals with idiopathic dilated cardiomyopathy, as well as the hearts of patients with AD. These findings suggest a potential systemic profile of proteinopathies and a new hypothesis for the link between peripheral and central symptoms of heart failure and AD. Herein, we provide an overview of the cardiovascular links to Alzheimer disease. (*Circ Res*. 2019;124:142-149. DOI: 10.1161/CIRCRESAHA.118.313563.)

Key Words: Alzheimer disease ■ atrial fibrillation ■ heart failure ■ inflammation ■ reactive oxygen species

Alzheimer disease (AD) is a progressive neurodegenerative disorder which accounts for about 70% of all dementia cases[1–3] and is projected to affect 13 million individuals in the United States by 2050.[3] It is characterized by the formation of senile plaques composed of aggregated Aβ (β-amyloid) fibers and neurofibrillary tangles formed by hyperphosphorylated tau protein, with associated neuronal inflammation, oxidative stress, and widespread degeneration of neurons. These physiological disruptions are accompanied by physical symptoms: memory loss, impaired cognitive function, personality and judgment disorder, speech abnormalities, and apraxia.[1]

A similar epidemiological profile characterizes heart failure (HF), a widespread public health problem, affecting 5.8 million individuals in the United States alone and nearly 23 million worldwide.[4] Obesity, sex, history of diabetes mellitus, and especially, age are risk factors for both HF and AD.[4–7] Genetic factors, such as the presence of the Apo E$_4$ (apolipoprotein E$_4$) allele and variants in the presenilin 1 (*PSEN1*) and presenilin 2 (*PSEN2*) genes are associated with the development of AD[8–10] and the same, as well as novel genetic variants of the *PSEN* genes, are associated with dilated cardiomyopathy.[11,12] Despite those similarities, much of the current understanding is centralized around the pathogenesis of AD via vascular factors and has failed to be extended to cardiac contributions. Vascular factors, such as macro and microinfarcts, white matter hyperintensities (WMH),

atherosclerosis, and hypertension that lead to decreased cerebral blood flow (CBF) before Aβ deposition would accelerate AD progression.[13]

Here, we reviewed the current knowledge on the vascular component and explore the new head to heart connection that could help defining cardiac abnormalities occurring in concert with the development of AD.

Vascular Role in AD

For years, the role of the vasculature in the progression of AD has prevailed as a main comorbidity contributing to AD. Vascular cognitive impairment remains a common risk factor of dementia as over half of all patients with vascular cognitive impairment will advance to dementia.[14,15] Thus, when attempting to explain the pathophysiology of AD, a vascular hypothesis arose in opposition to the amyloid cascade hypothesis.[16] The amyloid cascade hypothesis articulates that the pathology behind AD is driven by the deposition of the Aβ peptide in the brain.[17] However, supporters of the vascular hypothesis propose that AD is a vascular disorder, in which the pathology is induced via cerebral microvascular abnormalities.[18] In 1993, it was discovered that cerebral microvascular abnormalities led to a decrease in CBF, glucose metabolism, and oxygen consumption in AD patients.[19] de la Torre and Mussivand[19] established an inversely proportional relationship between these vascular abnormality symptoms and the severity of AD. In this study, they noted multiple different risk factors, such as aging,

Nonstandard Abbreviations and Acronyms	
Aβ	β-amyloid
AD	Alzheimer disease
Apo E$_4$	apolipoprotein E$_4$
APP	amyloid precursor protein
BBB	blood-brain barrier
CBF	cerebral blood flow
FPLC	fast performance liquid chromatography
HF	heart failure
iDCM	idiopathic dilated cardiomyopathy
IFN	interferon
IL	interleukin
PSEN1	presenilin 1
PSEN2	presenilin 2
ROS	reactive oxygen species
TNF	tumor necrosis factor
WMH	white matter hyperintensities

atherosclerosis, hyper/hypotension, and microvessel pathology; all of which are vascular risk factors that impair proper cerebral perfusion.[18]

Brain Hypoperfusion in the Pathogenesis of AD

It is commonly known that the brain relies on adequate blood supply (and thus oxygen) to maintain proper function.[20] It has been proposed that hypoxia and ischemia resulting from cerebral hypoperfusion is a direct contributor to the pathogenesis and development of AD.[20–22] Roher et al[22] observed total CBF to be 20% lower in the AD group compared with the nondemented control group, suggesting an association between brain hypoperfusion and dementia of AD. The same study found a decrease in pulse pressure in AD patients, further indicating a decrease in CBF, and consequently, a decrease in cognitive measures.[22] Nishimura et al[23] more specifically observed decreased CBF to the frontal lobe in correlation to both reduced cognitive function and progression of AD. The reduced cerebral perfusion causes a metabolic energy crisis because of the reduced oxygen exposure. This hypoxic state induces oxidative stress and acidosis eventually culminating in neuronal degradation.[24,25]

Oxidative Stress in AD

Contrary to popular belief, it has been discussed that a balanced reactive oxygen species (ROS) response actually promotes tissue repair via disinfection of existing tissue and stimulation of healthy tissue turnover.[26] However, the imbalanced metabolism of oxygen induced by this hypoxic state leads to excess ROS, resulting in deleterious effects.[27] Furthermore, the mitochondria of the vascular wall cells have been identified as the primary target of oxidative stress before development and progression of AD.[28]

However, it is believed that the accumulation of ROS and thereby oxidative stress, on neural tissue is a result of hypoperfusion in combination with Aβ proteotoxicity.[29] An increase in Aβ production has been linked to the progression of oxidative stress which can induce mitochondrial dysfunction. Work by Matsuoka et al[30] using transgenic mice

carrying mutant APP (amyloid precursor protein) and PSEN1 illustrates the key role of oxidative stress in the AD model. Additionally, 3-nitrotyrosine (protein oxidative stress marker) and 4-hydroxy-2-noneal (lipid oxidative stress marker) have been found to be increased with progressing levels of fibrillary Aβ.[30] Although most Aβ aggregations are found in extracellular regions, some collections of Aβ have been found in the mitochondria[31,32] of individuals with AD. This phenomenon may diminish mitochondrial function, specifically respiration and thereby increase the levels of ROS inside and potentially outside of the cell. Oxidative stress not only can induce further Aβ production but also triggers the production of tau protein, another critical component to the pathology of this disease.[31] Furthermore, it has been demonstrated that individuals with AD have decreased antioxidant levels, allowing higher levels of ROS to accumulate in the local environment.[29] This evidence, therefore, suggests a cyclic effect between Aβ aggregation and oxidative stress, driving the progression of AD and its physical symptoms.

Inflammation Contributes to Vascular Dysfunction and Neurodegeneration in AD

Another key aspect of the pathogenesis of AD as a result of reduced blood flow is inflammation. Changes in the vasculature either as a result of AD or part of an overall vasculopathy are associated with the release of multiple inflammatory factors, with cerebral microvessels secreting higher levels of TNF (tumor necrosis factor)-α, IL (interleukin)-1β, IL-6, and leukocyte adhesion molecules than non-AD controls.[33] However, despite the vast amount of literature focused on neural inflammation and its role in AD, no clear evidence has illuminated whether inflammation is a contributing factor towards the cause of AD, part of its pathology, or a secondary phenomenon.[34] However, it is widely accepted that the negative consequences of inflammation contribute towards the progression of AD, including neurodegeneration, and thereby diminished cognitive function. It is also understood that microglia, the resident macrophage in the brain, play a key role in the activation of the inflammatory response. Studies have illustrated that microglia are increased in individuals with AD and in transgenic mouse models. Although they exhibit heterogeneous phenotypes, it is understood that they are involved in Aβ maintenance.[35] Studies in vitro suggest that cytokine signaling and secretion from microglia can greatly impact the cerebral microenvironment and function of neurons. These cytokines—specifically IL-1β, IL-6, TNF-α, IFN (interferon)-γ—and various chemokines can strengthen the inflammatory response.[35] More recently, cytokine signaling in AD mouse models can have significant effects on amyloidosis, neurodegeneration, and cognition,[35] potentially disrupting the blood-brain barrier (BBB) in neurodegenerative disorders.[36] In AD pathology, the integrity of the BBB is reduced[37,38] as well. Whether as a result of the chronic cerebral inflammation or part of a larger systemic pathology, this defective BBB is believed to play a role in the pathogenesis of AD.

Structural Consequences of Hypoperfusion in the AD Brain

Furthermore, this same cerebral hypoperfusion has been found to break down the neurovascular unit, enabling progression

into neurodegenerative disorders like AD.[39] The neurovascular unit encompasses many different types of brain cells (endothelial, pericytes, and vascular smooth muscle cells), which in turn control the BBB.[39] Breakdown of the neurovascular unit would result in a dysfunctional BBB. Many recent studies have now correlated BBB dysfunction with the accrual of vasculotoxic molecules and hypoxia resulting from a decrease in CBF.[39]

Amyloid Directly Contributes to Cerebral Angiopathy

Changes in peripheral perfusion also have the potential to induce cerebral amyloid angiopathy—fibrillary amyloid deposition in small cerebral vessels. However, the exact mechanism whereby cerebral amyloid angiopathy contributes toward the pathogenesis of AD remains unknown. It has been reported that cerebral amyloid angiopathy can affect cell viability, induce apoptosis or oxidative stress, and trigger an inflammatory response.[40] Furthermore, cerebral amyloid angiopathy can create vascular dysfunction through hemorrhagic complications or blocking blood flow (resulting in cerebral ischemia). These events, either alone or in combination, may contribute towards the progression of AD.[40]

Atherosclerosis, Hypertension, and Ischemia Cascade Effects in AD

Additionally, for many decades, the role of decreased CBF in the pathogenesis of AD relied on the impairment of vasculature through the lens of atherosclerosis.[10,14] Similarities between AD and atherosclerosis have sparked investigation considering that both are found in conjunction with vascular wall thickening and blood vessel occlusion.[41] After examination of the cerebral arteries in AD patients, Roher et al[42] found cases of significantly increased cerebral artery occlusion in comparison to control groups.[41] Additionally, a positive correlation was determined between arterial stenosis and neurofibrillary tangles,[42] which is a hallmark of AD. Other studies by Roher et al[43] found more widespread intracranial atherosclerosis in AD patients versus nondemented patients. Cognitive dysfunction was also found to be exacerbated in AD patients with cerebral atherosclerosis compared with nonatherosclerotic AD patients, regardless of intracranial or extracranial localization.[44] Furthermore, the Nun Study of Aging and AD indicated that patients with multiple brain infarctions have lower cognitive function and higher prevalence of dementia.[45,46]

Hypertension has been independently identified as a risk factor for AD, but many have reasoned that this is because of hypertension leading to other diseases, which then result in the onset of dementia.[45] Throughout time, there have been multiple intuitions about the exact mechanism of hypertension leading to AD: (1) vascular alterations leading to infarcts in the brain, (2) adverse effects on neuronal health leading to deposition of Aβ in the brain, and lastly (3) development of cardiovascular disease giving rise to AD.[45] Hypertension has also been proposed to evoke AD via ischemia, oxidative stress, inflammation, and small-vessel disease.[47,48] More recently, hypertension has been largely noted as the most detrimental vascular risk in the progression of AD.[49] This designation is because of its causation of small-vessel disease, which later

results in lacunar infarcts, white matter lesions/hyperintensities, and microinfarcts,[50] all of which are indicated in AD and accelerate the reduction in CBF.[51] Hypertension, however, is an independent risk factor for cardiovascular diseases, including HF,[52] indirectly affecting AD through the old lens of cerebral hypoperfusion and the new one of the common pathogenesis of AD and HF as age-related proteinopathies.

One of the main hallmarks of cerebrovascular disease is found in the microvascular structural changes, namely WMH,[53] a manifestation of small-vessel disease.[54] WMH are a commonality with age progression and a causative agent behind normal cognitive decline.[55] However, as imaging and other diagnostic techniques have progressed, it has been shown that small-vessel disease and WMHs in the brain both play a role in the development of AD.[56] Population studies using magnetic resonance imaging have also designated a high occurrence of small-vessel disease being associated with higher risk of stroke and dementia.[20] These WMH are indicative of vascular lesions and have been found to lower the threshold for the clinical diagnosis of AD.[20] Tosto et al[55] established that WMH distributions in the brain can progress to AD both directly via neurodegenerative changes and indirectly via aggravation of the tau effect on clinical transformation. This connection has enabled vascular risk factors to be common targets when testing novel therapeutic approaches against AD, such as hypertension and cholesterol treatments.[57] However, these studies have been preliminary, and there is much more to be investigated.

In summary, the role of the vasculature in AD progression is one that is implicated primarily via decreased CBF. This remains the main talking point for the vascular hypothesis of AD, which, as seen in Figure 1, claims that many vascular risk factors exert their pathology through cerebral hypoperfusion.[58] However, there is a multitude of contributing vascular risk factors, some of which include atherosclerosis, hypertension, small-vessel disease, and BBB dysfunction, all contributing to reduced CBF and the progression of AD, as shown in Figure 1. Much of the discussed literature has focused solely on the vasculature and the brain; however, it was recently proposed that there is a closer link between the brain and the heart than originally expected.[59]

Newly Discovered Link Between HF and AD

Until recently, the only clear link between HF and AD was based on epidemiological data indicating that both of these debilitating conditions have a high incidence of coexisting, especially among older patients. Furthermore, both of these conditions share risk factors; some of which include obesity, sex, high cholesterol, and more importantly age. As described above, a link to cognitive impairment in HF was also recognized in cerebral hypoperfusion and anoxic state.[2,60,61] This theory follows a cascade effect: HF leads to decreased CBF, causing a metabolic energy crisis. This, in turn, causes acidosis and oxidative stress in multiple regions of the brain, eventually culminating in neuronal degradation.[24,25,62] Notably, the severity of HF has been shown to positively correlate with the degree of cognitive decline,[63,64] and neuroimaging studies have demonstrated a link between HF and structural changes to the brain.[25,65] Individuals with HF often exhibit regional

Amylin, a 37-residue peptide hormone, cosecreted with insulin in 100:1 from pancreas

Figure 1. The vascular hypothesis of Alzheimer disease (AD) proposes that multiple vascular risk factors (atherosclerosis, inflammation, hypertension, and small-vessel disease, etc) result in decreased cerebral blood flow (CBF). The reduced CBF proceeds to induce white matter hyperintensities and cerebral microinfarctions that ultimately contribute to the progression of AD. Furthermore, it has been proposed that oxidative stress, resultant of reduced CBF, can contribute to AD progression in conjunction with Aβ (β-amyloid) deposits. BBB indicates blood-brain barrier; and NVU, neurovascular unit.

brain atrophy and demyelination, as well as impaired axonal circuit functionality.[25,65,66]

However, cognitive impairment in HF may have a more complex pathogenic background. In fact, in a more general scope, misfolded protein disease is not limited to the brain.[59,67]

Amylin Cardiomyopathy: a Direct Link Between Heart and Brain Failure

Recent studies focusing on hyperamylinemia, a common disorder in diabetic patients, have revealed a more complex systemic pathogenesis of aggregating amylin. Previous work has found evidence of amylin/amyloid aggregations in the hearts of patients with diabetic cardiomyopathy.[68] Work by Jackson et al[69,70] sought to examine the cerebrovascular tissue of diabetic patients with vascular dementia of AD for amyloid deposits, wherein they found amylin oligomers and plaques in the temporal gray matter from diabetic patients. Furthermore, researchers found amylin deposition in the brain vasculature and parenchyma of individuals in a specific test group with late-onset AD and no apparent diabetes mellitus.[69] Jackson et al[69] also found some instances where amylin and Aβ depositions were mixed. Expanding on this finding, it has been suggested that amylin and Aβ are connected in terms of wider net pathophysiology. This hypothesis is supported by the fact that both Aβ and amylin can form similar functioning toxic aggregates that can induce inflammation, oxidative stress, and changes in the microvasculature of brain parenchyma.[68,69,71] These findings suggest that amylin deposition, and thereby its negative effects on the vasculature and parenchyma of the brain, may participate in the progression of AD.

Common Genetic Profiles Between AD and HF

The concept of AD affecting both the head and heart is reinforced when looking at genetic profiles between connected disease states. Research has shown that there are similar genetic profiles between HF and AD. Work by Li et al[11] found that in the familial forms, these 2 conditions share variations in the *PSEN1* or *PSEN2* genes. In this specific study, a *PSEN1* missense mutation (Asp333Gly) and a *PSEN2* missense mutation (Ser130Leu) were associated with both DCM and HF.[11] Similarly, Gianni et al[12] identified the same missense mutations in the *PSEN1* and *PSEN2* genes associated with AD in sporadic cases of idiopathic dilated cardiomyopathy (iDCM) and described new genetic variants of the promoter region of the genes affecting the expression levels of the protein. In this study, Gianni et al[12] discovered plaque-like amyloid deposits in the hearts of patients with iDCM. These aggregations of proteins hold a considerable degree of proteotoxicity, inducing cell death.[72] At the microscale, Demuro et al[73] investigated the biochemical mechanisms by which aggregations of soluble amyloid proteins have a neurotoxic effect. Their findings suggest that oligomer amyloid aggregations can disrupt calcium flux homeostasis and thereby cell membrane function.[73] Similar to this proteotoxic effect in neurons, oligomeric aggregates exercise the same effect on cardiomyocyte Ca^{2+} homeostasis.[12] The toxic role of amyloid deposition as a causal agent for AD was challenged by the failure of some clinical trials targeting amyloid plaques for efficacy of clinical symptoms (the immunoglobulin/albumin combination flebogamma/albutein, and small molecule targeting the beta-secretase 1 cleaving enzyme verubecestat) or causing side effects, such as encephalopathy (the humanized anti-Aβ mAb gantenerumab). An initial explanation for the failure of the trials, and therefore the failure of the amyloid theory altogether, included late administration of the drug when the amyloid had triggered neuronal cell death and other terminal changes. However, more recent trials targeting multiple forms of Aβ, such as oligomers in addition to the insoluble fibrils (the mAb crenezumab, aducanumab), did not cause side effects and provided some evidence of clearance of plaques and decline of clinical symptoms. Although waiting for the ongoing phase III clinical trial results (eg, for crenezumab, aducanumab, the BACE (beta site amyloid precursor protein cleaving enzyme)

Seemingly anywhere with significant blood flow, especially via capillaries

Figure 2. Overall schematic summary of the new findings on the head to heart connection in Alzheimer disease bringing attention to either a more systemic profile or a metastatic condition. This closer connection has some main tenants: (1) A shared genetic profile with presenilin 1 (*PSEN1*) and PSEN2 isoforms; (2) Discovery of aggregations of Aβ (β-amyloid) and amylin in peripheral tissue and their proteotoxic effects.

inhibitors lanabecestatand elenbecestat) in vitro studies from the del Monte laboratory using atomic force microscopy suggested that a possible explanation for the failure of some of the drugs may reside in targeting fibers versus the more toxic oligomeric species. The study indicated that although dissolving fibers may result in increased release of toxic species, targeting the latter may at least slow the progression of the disease by removing the source of neuronal poison.[74]

Additional Common Protein Profiles Between AD and HF

Focusing on the heart, the del Monte laboratory analyzed the composition of the aggregates in the myocardium of iDCM patients and identified that cofilin-2—along with its substrate actin and competing protein MLCII (myosin regulatory light chain 2)—was sequestered in the aggregates.[75] Cofilin is an actin-depolymerization protein that regulates the turnover of actin in contractile cells and the structural integrity of the cell. In a defective and sequestered state, this protein is also known to play a role in multiple neurodegenerative diseases, such as corticobasal degeneration, William syndrome, fragile X syndrome, and spinal muscular atrophy,[12,59,75] as well as other cardiac disorders, such as myocardial ischemia. Recently, the Salloum laboratory described similar changes in cofilin activity, as described in iDCM patients with end-stage ischemic cardiomyopathy.[76] This new evidence further supports the link between neurodegenerative disease and various cardiovascular diseases leading to HF.

After this work, del Monte's group[59] analyzed the complex pathology of proteinopathies and sought to discover a closer link between HF and AD by examining the hearts of individuals with AD diagnosis. In this work, Troncone et al[59] analyzed the hearts and brains of patients with AD. On investigation, they discovered in the heart, Aβ (both $A\beta_{40}$ and $A\beta_{42}$) structurally akin to those found in the brain and, in a retrospective analysis, found that AD patients present with myocardial diastolic dysfunction. Thus, like in traditional cardiac amyloidosis, the pathophysiology of diastolic dysfunction in AD can be described by the accumulation of misfolded proteins in the heart.[77]

The concept of peripheral accumulation of Aβ in patients with AD is not restricted to the heart. In fact, an early study by Joachim et al[78] analyzed Aβ deposition in nonneuronal tissue—most notably, skin and intestine. Eight of the samples from test subjects with AD showed clear and definite evidence of Aβ deposition in these peripheral tissues. Similarly, $A\beta_{40}$ and $A\beta_{42}$ aggregates were identified in skeletal muscle of AD individuals using fast performance liquid chromatographic (FPLC) size exclusion chromatography. Researchers discovered elevated levels of Aβ in the temporalis muscles of AD individuals, indicating a possible contributor to elevated concentrations of Aβ plasma levels and potentially indirectly contributing to Aβ deposits in cerebral blood vessels and brain parenchyma.[79] Furthermore, these varying levels of Aβ suggest an alteration in APP or Aβ metabolism in peripheral tissues outside of the central nervous system.[79]

Viewing AD with a new lens as a potential multiorgan disease,[59] as shown in Figure 2, it is possible that an inflamed

Table. Cardiovascular Problems Linked to AD

Heart failure	Similar epidemiological profile to AD, with linked risk factors: obesity, sex, and age.[4–7]
	Specifically in the case of patients with iDCM, there exists a common genetic (PSEN1 and PSEN2 genetic variants) and physiological link about the aggregation of amyloid protein in heart/brain.[12,57]
AF	Similar epidemiological profile to AD.
	Chronic AF may lead to hypoperfusion and thereby induce acceleration of β-amyloid plaque formation.[80]
Hypertension	Hypertension has been linked as risk factor for AD, but the mechanism is poorly understood.
	It is believed to either occur through
	Vascular altercations leading to infarcts in the brain
	Development of other cardiovascular disease
	Adverse effects on neuronal health leading to beta amyloid deposition in brain.[44,46,47]
Vasculopathy	Macro and micro infarcts, white matter hyperintensities, atherosclerosis, and hypertension → leading to decreased cerebral blood flow can accelerate AD pathogenesis and neurodegenerative symptoms.

AD indicates Alzheimer disease; AF, atrial fibrillation; iDCM, idiopathic dilated cardiomyopathy; and PSEN, presenilin.

and acidic cerebral microenvironment potentially contributes to a defective BBB (a common symptom of AD). This impaired BBB allows permeability of Aβ plaques into the bloodstream. This spreading event in combination with a defective production/clearance homeostasis of misfolded proteins would cause a combination of central nervous system and peripheral symptoms. In the case of HF, the involvement of the heart would accelerate the progression of the disease by contributing to the oxidative stress and acidosis via brain hypoperfusion. However, there might be a possible specific genetic profile—including a miRNA (micro RNA) signature—that accounts for the systemic link between the head and the peripheral organs (Table).

Conclusions

With recent studies discovering pathogenic mechanisms and possible links between AD and iDCM, including genetic and environmental background, and that AD individuals had significant amounts of Aβ plaques in peripheral organs, it is critical to understand the contribution of the peripheral organs to the overall clinical picture of proteostatic diseases. The failing heart, by reducing CBF to peripheral organs, but also by sustaining the spread of the pathological fragments together with other peripheral organs, activates or aggravates aggregate pathology in the brain. Thus, within this new framework, understanding the disease in its entirety may help in discovering new approaches to delay or reverse proteinopathies involving these 2 vital organs.

Sources of Funding

Disclosures

None.

References

1. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. *JAMA*. 1997;278:1363–1371.
2. Fratiglioni L, De Ronchi D, Agüero-Torres H. Worldwide prevalence and incidence of dementia. *Drugs Aging*. 1999;15:365–375. doi: 10.2165/00002512-199915050-00004
3. Castellani RJ, Rolston RK, Smith MA. Alzheimer disease. *Dis Mon*. 2010;56:484–546. doi: 10.1016/j.disamonth.2010.06.001
4. Roger VL. Epidemiology of heart failure. *Circ Res*. 2013;113:646–659. doi: 10.1161/CIRCRESAHA.113.300268
5. Viña J, Lloret A. Why women have more Alzheimer's disease than men: gender and mitochondrial toxicity of amyloid-beta peptide. *J Alzheimers Dis*. 2010;20(suppl 2):S527–S533. doi: 10.3233/JAD-2010-100501
6. Hölscher C. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. *Biochem Soc Trans*. 2011;39:891–897. doi: 10.1042/BST0390891
7. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kåreholt I, Winblad B, Helkala EL, Tuomilehto J, Soininen H, Nissinen A. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. *Arch Neurol*. 2005;62:1556–1560. doi: 10.1001/archneur.62.10.1556
8. Van Uden E, Kang DE, Koo EH, Masliah E. LDL receptor-related protein (LRP) in Alzheimer's disease: towards a unified theory of pathogenesis. *Microsc Res Tech*. 2000;50:268–272. doi: 10.1002/1097-0029(20000815)50:4<268::AID-JEMT3>3.0.CO;2-1
9. Pang CP, Baum L. Lipoproteins and related molecules in Alzheimer's disease. *Microsc Res Tech*. 2000;50:259–260. doi: 10.1002/1097-0029(20000815)50:4<259::AID-JEMT1>3.0.CO;2-9
10. Iadecola C. The pathobiology of vascular dementia. *Neuron*. 2013;80:844–866. doi: 10.1016/j.neuron.2013.10.008
11. Li D, Parks SB, Kushner JD, Nauman D, Burgess D, Ludwigsen S, Partain J, Nixon RR, Allen CN, Irwin RP, Jakobs PM, Litt M, Hershberger RE. Mutations of presenilin genes in dilated cardiomyopathy and heart failure. *Am J Hum Genet*. 2006;79:1030–1039. doi: 10.1086/509900
12. Gianni D, Li A, Tesco G, et al. Protein aggregates and novel presenilin gene variants in idiopathic dilated cardiomyopathy. *Circulation*. 2010;121:1216–1226. doi: 10.1161/CIRCULATIONAHA.109.879510
13. Snyder HM, Corriveau RA, Craft S, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. *Alzheimers Dement*. 2015;11:710–717. doi: 10.1016/j.jalz.2014.10.008
14. Wentzel C, Rockwood K, MacKnight C, Hachinski V, Hogan DB, Feldman H, Østbye T, Wolfson C, Gauthier S, Verreault R, McDowell I. Progression of impairment in patients with vascular cognitive impairment without dementia. *Neurology*. 2001;57:714–716.
15. Jellinger KA. Understanding the pathology of vascular cognitive impairment. *J Neurol Sci*. 2005;229-230:57–63. doi: 10.1016/j.jns.2004.11.029
16. Rius-Pérez S, Tormos AM, Pérez S, Taléns-Visconti R. Vascular pathology: cause or effect in Alzheimer disease? *Neurologia*. 2018;33:112–120. doi: 10.1016/j.nrl.2015.07.010
17. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. *Nat Rev Drug Discov*. 2011;10:698–712. doi: 10.1038/nrd3505
18. de la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. *Stroke*. 2002;33:1152–1162.
19. de la Torre JC, Mussivand T. Can disturbed brain microcirculation cause Alzheimer's disease? *Neurol Res*. 1993;15:146–153.
20. Gorelick PB, Scuteri A, Black SE, et al; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2011;42:2672–2713. doi: 10.1161/STR.0b013e3182299496
21. de la Torre JC. Cerebrovascular and cardiovascular pathology in Alzheimer's disease. *Int Rev Neurobiol*. 2009;84:35–48.
22. Roher AE, Debbins JP, Malek-Ahmadi M, et al. Cerebral blood flow in Alzheimer's disease. *Vasc Health Risk Manag*. 2012;8:599–611. doi: 10.2147/VHRM.S34874
23. Nishimura T, Hashikawa K, Fukuyama H, Kubota T, Kitamura S, Matsuda H, Hanyu H, Nabatame H, Oku N, Tanabe H, Kuwabara Y, Jinnouchi S, Kubol A. Decreased cerebral blood flow and prognosis of Alzheimer's disease: a multicenter HMPAO-SPECT study. *Ann Nucl Med*. 2007;21:15–23.
24. Moreira PI, Smith MA, Zhu X, Nunomura A, Castellani RJ, Perry G. Oxidative stress and neurodegeneration. *Ann N Y Acad Sci*. 2005;1043:545–552. doi: 10.1196/annals.1333.062
25. Cermakova P, Eriksdotter M, Lund LH, Winblad B, Religa P, Religa D. Heart failure and Alzheimer's disease. *J Intern Med*. 2015;277:406–425. doi: 10.1111/joim.12287
26. Bryan N, Ahswin H, Smart N, Bayon Y, Wohlert S, Hunt JA. Reactive oxygen species (ROS)–a family of fate deciding molecules pivotal in constructive inflammation and wound healing. *Eur Cell Mater*. 2012;24:249–265.
27. Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. *Curr Neuropharmacol*. 2009;7:65–74. doi: 10.2174/157015909787602823
28. Zhu X, Smith MA, Honda K, Aliev G, Moreira PI, Nunomura A, Casadesus G, Harris PL, Siedlak SL, Perry G. Vascular oxidative stress in Alzheimer disease. *J Neurol Sci*. 2007;257:240–246. doi: 10.1016/j.jns.2007.01.039
29. Kim GH, Kim JE, Rhie SJ, Yoon S. The role of oxidative stress in neurodegenerative diseases. *Exp Neurobiol*. 2015;24:325–340. doi: 10.5607/en.2015.24.4.325
30. Matsuoka Y, Picciano M, La Francois J, Duff K. Fibrillar beta-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease. *Neuroscience*. 2001;104:609–613.

31. Zhao Y, Zhao B. Oxidative stress and the pathogenesis of Alzheimer's disease. *Oxid Med Cell Longev*. 2013;2013:316523.

32. de la Monte SM, Wands JR. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. *J Alzheimers Dis*. 2006;9:167–181.

33. Rius-Pérez S, Tormos AM, Pérez S, Taléns-Visconti R. Vascular pathology: cause or effect in Alzheimer disease? *Neurología (English Edition)*. 2018;33:112–120.

34. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. *Cold Spring Harb Perspect Med*. 2012;2:a006346. doi: 10.1101/cshperspect. a006346

35. Combs CK. Inflammation and microglia actions in Alzheimer's disease. *J Neuroimmune Pharmacol*. 2009;4:380–388. doi: 10.1007/s11481-009-9165-3

36. Varatharaj A, Galea I. The blood-brain barrier in systemic inflammation. *Brain Behav Immun*. 2017;60:1–12. doi: 10.1016/j.bbi.2016.03.010

37. Ujiie M, Dickstein DL, Carlow DA, Jefferies WA. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. *Microcirculation*. 2003;10:463–470. doi: 10.1038/sj. mn.7800212

38. Clifford PM, Zarrabi S, Siu G, Kinsler KJ, Kosciuk MC, Venkataraman V, D'Andrea MR, Dinsmore S, Nagele RG. Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. *Brain Res*. 2007;1142:223–236. doi: 10.1016/j.brainres. 2007.01.070

39. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. *Nat Rev Neurosci*. 2011;12:723–738. doi: 10.1038/nrn3114

40. Ghiso J, Tomidokoro Y, Revesz T, Frangione B, Rostagno A. Cerebral amyloid angiopathy and Alzheimer's disease. *Hirosaki Igaku*. 2010;61:S111–S124.

41. Lathe R, Sapronova A, Kotelevtsev Y. Atherosclerosis and Alzheimer– diseases with a common cause? Inflammation, oxysterols, vasculature. *BMC Geriatr*. 2014;14:36. doi: 10.1186/1471-2318-14-36

42. Roher AE, Esh C, Kokjohn TA, Kalback W, Luehrs DC, Seward JD, Sue LI, Beach TG. Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. *Arterioscler Thromb Vasc Biol*. 2003;23:2055–2062. doi: 10.1161/01.ATV.0000095973.42032.44

43. Roher AE, Tyas SL, Maarouf CL, Daugs ID, Kokjohn TA, Emmerling MR, Garami Z, Belohlavek M, Sabbagh MN, Sue LI, Beach TG. Intracranial atherosclerosis as a contributing factor to Alzheimer's disease dementia. *Alzheimers Dement*. 2011;7:436–444. doi: 10.1016/j.jalz.2010.08.228

44. Kim TW, Song IU, Jeong DS, Lee KS. Clinical effect of cerebrovascular atherosclerosis on cognition in Alzheimer's disease. *Arch Gerontol Geriatr*. 2016;63:55–58. doi: 10.1016/j.archger.2015.11.009

45. Dickstein DL, Walsh J, Brautigam H, Stockton SD Jr, Gandy S, Hof PR. Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. *Mt Sinai J Med*. 2010;77:82–102. doi: 10.1002/msj.20155

46. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. *JAMA*. 1997;277:813–817.

47. Leszek J, Sochocka M, Gąsiorowski K. Vascular factors and epigenetic modifications in the pathogenesis of Alzheimer's disease. *J Neurol Sci*. 2012;323:25–32. doi: 10.1016/j.jns.2012.09.010

48. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Jolles J, Koudstaal PJ, Hofman A, Breteler MM. Cerebral small-vessel disease and decline in information processing speed, executive function and memory. *Brain*. 2005;128:2034–2041. doi: 10.1093/brain/awh553

49. Thorin E. Hypertension and Alzheimer disease: another brick in the wall of awareness. *Hypertension*. 2015;65:36–38. doi: 10.1161/HYPERTENSIONAHA.114.04257

50. Faraco G, Iadecola C. Hypertension: a harbinger of stroke and dementia. *Hypertension*. 2013;62:810–817. doi: 10.1161/HYPERTENSIONAHA. 113.01063

51. de la Torre JC. Cerebral hemodynamics and vascular risk factors: setting the stage for Alzheimer's disease. *J Alzheimers Dis*. 2012;32:553–567.

52. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D; Framingham Heart Study. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. *Circulation*. 2002;106:3068–3072. doi: 10.1161/01.CIR.0000039105.49749.6F

53. Vemuri P, Lesnick TG, Przybelski SA, et al. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. *Brain*. 2015;138:761–771. doi: 10.1093/brain/awu393

54. Tuladhar AM, van Norden AG, de Laat KF, Zwiers MP, van Dijk EJ, Norris DG, de Leeuw FE. White matter integrity in small vessel disease is related to cognition. *Neuroimage Clin*. 2015;7:518–524. doi: 10.1016/j.nicl.2015.02.003

55. Tosto G, Zimmerman ME, Hamilton JL, Carmichael OT, Brickman AM; Alzheimer's Disease Neuroimaging Initiative. The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment. *Alzheimers Dement*. 2015;11:1510–1519. doi: 10.1016/j.jalz.2015.05.014

56. Cai Z, Wang C, He W, Tu H, Tang Z, Xiao M, Yan LJ. Cerebral small vessel disease and Alzheimer's disease. *Clin Interv Aging*. 2015;10:1695–1704. doi: 10.2147/CIA.S90871

57. O'Brien JT, Markus HS. Vascular risk factors and Alzheimer's disease. *BMC Med*. 2014;12:218. doi: 10.1186/s12916-014-0218-y

58. de la Torre JC. The vascular hypothesis of Alzheimer's disease: bench to bedside and beyond. *Neurodegener Dis*. 2010;7:116–121.

59. Troncone L, Luciani M, Coggins M, Wilker EH, Ho CY, Codispoti KE, Frosch MP, Kayed R, Del Monte F. Aβ amyloid pathology affects the hearts of patients with Alzheimer's disease: mind the heart. *J Am Coll Cardiol*. 2016;68:2395–2407. doi: 10.1016/j.jacc.2016.08.073

60. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Odén A, Svanborg A. 15-year longitudinal study of blood pressure and dementia. *Lancet*. 1996;347:1141–1145.

61. Jagust W. Untangling vascular dementia. *Lancet*. 2001;358:2097–2098. doi: 10.1016/S0140-6736(01)07230-0

62. Pirchl M, Humpel C. [Does acidosis in brain play a role in Alzheimer's disease?]. *Neuropsychiatr*. 2009;23:187–192.

63. Hoth KF, Poppas A, Moser DJ, Paul RH, Cohen RA. Cardiac dysfunction and cognition in older adults with heart failure. *Cogn Behav Neurol*. 2008;21:65–72. doi: 10.1097/WNN.0b013e3181799dc8

64. Cohen MB, Mather PJ. A review of the association between congestive heart failure and cognitive impairment. *Am J Geriatr Cardiol*. 2007;16:171–174.

65. Vogels RL, van der Flier WM, van Harten B, Gouw AA, Scheltens P, Schroeder-Tanka JM, Weinstein HC. Brain magnetic resonance imaging abnormalities in patients with heart failure. *Eur J Heart Fail*. 2007;9:1003–1009. doi: 10.1016/j.ejheart.2007.07.006

66. Kumar R, Woo MA, Macey PM, Fonarow GC, Hamilton MA, Harper RM. Brain axonal and myelin evaluation in heart failure. *J Neurol Sci*. 2011;307:106–113. doi: 10.1016/j.jns.2011.04.028

67. Wang J, Gu BJ, Masters CL, Wang YJ. A systemic view of Alzheimer disease - insights from amyloid-β metabolism beyond the brain. *Nat Rev Neurol*. 2017;13:612–623. doi: 10.1038/nrneurol.2017.111

68. Despa F, Decarli C. Amylin: what might be its role in Alzheimer's disease and how could this affect therapy? *Expert Rev Proteomics*. 2013;10:403–405. doi: 10.1586/14789450.2013.841549

69. Jackson K, Barisone GA, Diaz E, Jin LW, DeCarli C, Despa F. Amylin deposition in the brain: a second amyloid in Alzheimer disease? *Ann Neurol*. 2013;74:517–526. doi: 10.1002/ana.23956

70. Jackson G, Gibbs CR, Davies MK, Lip GYH. Pathophysiology. *BMJ*. 2000;320:167–170.

71. Kawahara M, Kuroda Y, Arispe N, Rojas E. Alzheimer's beta-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. *J Biol Chem*. 2000;275:14077–14083.

72. Parry TL, Melehani JH, Ranek MJ, Willis MS. Functional amyloid signaling via the inflammasome, necrosome, and signalosome: new therapeutic targets in heart failure. *Front Cardiovasc Med*. 2015;2:25. doi: 10.3389/fcvm.2015.00025

73. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. *J Biol Chem*. 2005;280:17294–17300. doi: 10.1074/jbc.M500997200

74. Bernini F, Malferrari D, Pignataro M, Bortolotti CA, Di Rocco G, Lancellotti L, Brigatti MF, Kayed R, Borsari M, Del Monte F, Castellini E. Pre-amyloid oligomers budding:a metastatic mechanism of proteotoxicity. *Sci Rep*. 2016;6:35865. doi: 10.1038/srep35865

75. Subramanian K, Gianni D, Balla C, Assenza GE, Joshi M, Semigran MJ, Macgillivray TE, Van Eyk JE, Agnetti G, Paolocci N, Bamburg JR, Agrawal PB, Del Monte F. Cofilin-2 phosphorylation and sequestration in myocardial aggregates: novel pathogenetic mechanisms for idiopathic dilated cardiomyopathy. *J Am Coll Cardiol*. 2015;65:1199–1214. doi: 10.1016/j.jacc.2015.01.031

76. Chau VQ, Devarakonda T, Romeo F, Balan B, Cain C, Toldo S, Tang D, Shah K, Kasirajan V, Salloum FN. Cardiac expression profiles of cofilin-2 and H$_2$S-producing enzyme 3-mercaptopyruvate sulfurtransferase

in patients with end-stage ischemic cardiomyopathy [abstract 16744]. *Circulation.* 2017;136:A16744.

77. Willis MS, Patterson C. Proteotoxicity and cardiac dysfunction–Alzheimer's disease of the heart? *N Engl J Med.* 2013;368:455–464. doi: 10.1056/NEJMra1106180

78. Joachim CL, Mori H, Selkoe DJ. Amyloid beta-protein deposition in tissues other than brain in Alzheimer's disease. *Nature.* 1989;341:226–230. doi: 10.1038/341226a0

79. Kuo YM, Kokjohn TA, Watson MD, Woods AS, Cotter RJ, Sue LI, Kalback WM, Emmerling MR, Beach TG, Roher AE. Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism. *Am J Pathol.* 2000;156: 797–805.

80. Ihara M, Washida K. Linking atrial fibrillation with Alzheimer's disease: epidemiological, pathological, and mechanistic Evidence. *J Alzheimers Dis.* 2018;62:61–72. doi: 10.3233/JAD-170970

It seems that there are strong evidences about the direct connection between heart failure (and related diseases) and AD. It appears from the review that soluble amyloid oligomers and insoluble fibrils might be the link to ostensibly connect the two diseases from the clinical perspective. These materials may be produced and circulated throughout the body, depositing in various tissues and organs, including the heart and brain (especially via compromised BBB).

There might be various reasons for the proteins (a-beta, alpha synuclein, tau, immunoglubin light chain, etc.) to unfold, oligomerize, and aggregate.
There have been various studies to look for biochemical causes, but it might be overlooked to examine the possible cause by hemodynamic and mechanical stress and disturbance. As we have been proposing, shear stress and/or fluid pressure could cause the proteins to (partially) unfold and thus become more prone to self-assembly.

Other possible reasons for directly triggering amyloid formation:

* local concentration (obviously; more input and less drainage)
* pH (acidic ?)
* ionic strength (salt)
* aldehyde (chemical linker or promoter for unfolding)
* temperature (lower temperature induces precipitation)
* nucleation seeding (structurally similar amyloids or fibrils)
*